Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading Update

25 Oct 2019 07:00

RNS Number : 0931R
Synthomer PLC
25 October 2019
 

 

October 25th 2019

 

Synthomer plc

Q3 Trading Update

Continued challenges in European SBR market; Revised FY outlook

 

Synthomer plc ("Synthomer" or "the Group") today issues a trading update for the third quarter ("Q3") ended September 30th 2019.

 

Trading

 

The growing weakness in the global economy has created a more challenging backdrop for the Chemical industry. Depressed European industrial activity combined with increased political and economic uncertainties have resulted in an overall slower trading environment throughout Q3.

 

Performance Elastomers

 

In this environment, Nitrile Butadiene Latex (NBR) had another positive quarter with continued growth supported by the additional 90 ktes of capacity introduced during Q4 2018. NBR volumes increased further during Q3 with year-to-date unit margins remaining stable.

 

In SBR, the Group highlighted challenging conditions in Europe at its H1 results in August. Conditions have not improved during Q3 and the Group's Paper segment has also continued to remain particularly weak. Accordingly, management now expect SBR volumes to be approximately 10% behind 2018 and unit margins to also be similarly lower than last year. A review of network utilisation is currently underway and an update on asset re-purposing and cost base will be provided in conjunction with the Full Year results in March 2020.

 

Functional Solutions

 

Notwithstanding the impact of tough market conditions, overall performance was in line with the first nine months of 2018, with lower volumes offset by higher unit margins. The Group expects to see the benefits of additional capacity at Worms (Germany) and Roebuck (USA) continue to come through in line with the investment case.

 

Industrial Specialities

 

Industrial Specialities continued to trade in-line with management expectations. Volumes and margins were broadly flat with the first nine months of 2018.

 

Financial position

 

At 30 September 2019, the Group remained conservatively levered with net debt/EBITDA, excluding the net proceeds of the rights issue, of 1.4x (30 September 2018: 1.4x).

 

Proposed acquisition of Omnova Solutions Inc.

 

Following approval by both sets of shareholders and competition clearance in the US, the transaction remains subject only to regulatory approval from the European and Turkish competition authorities, and the Group continues to target completion in late 2019.

 

There has been no material change to the expected de-leveraging profile of the Enlarged Group as announced at the time of the transaction.

 

Management remain confident of delivering a swift integration and synergies during 2020.

 

2019 Outlook

 

Whilst Synthomer continues to benefit from its strong product portfolio, end market diversification and geographic presence, the slower trading environment is expected to continue through the remainder of the year and into 2020, particularly in Europe.

 

Whilst Functional Solutions and Industrial Specialities are now expected to be in-line with the prior year, with NBR ahead of 2018, results for the Full Year will be adversely impacted by the increased weakness in the European SBR business.

 

If the current weakness in macroeconomic conditions persist through Q4, excluding any impact from the potential acquisition of OMNOVA, the Board expects underlying profit before tax for FY 2019 to be approximately 10% below 2018 and accordingly current consensus expectations*.

 

- Ends -

 

* Teneo compiled Company consensus: FY 2019 underlying profit before tax - £135.3m

 

Enquiries:

 

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, Head of Investor Relations

 

Tel: + 44 1279 436211

Charles Armitstead, Teneo

Tel: + 44 7703 330 269

 

The Company will hold a conference call for investors and analysts at 0800 BST today:

Dial in number: 08003589473 PIN: 25297905#

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUWRKUARUAA
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.